Drugs that raise HDL confer no extra clinical benefit when added to a statin

mdCurrent Conference Report: American College of Cardiology's 61st Annual Scientific Session & Expo

Adding a therapy that boosts the level of high-density lipoprotein (HDL) cholesterol in a patient already taking a statin is unlikely to produce a substantial clinical benefit, according to the results of a meta-regression analysis.

Key Point: More evidence is required on the effects of raising HDL cholesterol levels in patients on a statin before this practice can be recommended.

Brian A. Ference, MD, MPhil, MSc, and colleagues from Wayne State University in Detroit presented the results of their analysis at the 61st annual scientific session of the American College of Cardiology, held in Chicago, Illinois, United States. The study also was published in the Journal of the American College of Cardiology.

The investigators analyzed 26 statin trials that included 169,138 participants and estimated the effect of raising HDL cholesterol on major...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Cardiology, Cardiovascular Disease, Non-Communicable Disease, Pharmacology, Primary Care and tagged , , , , , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.